Business Context and Reporting Period
This Form 8-K is a current report filed by Revelation Biosciences, Inc. on September 24, 2024. The filing reports a specific corporate event rather than a standard financial reporting period. The Company is an emerging growth company incorporated in Delaware with principal executive offices in San Diego, California.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to disclose a material event regarding the Company's clinical development program.
Material Changes
The material change reported is the issuance of a press release on September 24, 2024, titled "Gemini Induces Dose Dependent Significant Increases in IL-10." This indicates a clinical development milestone for the Company's product candidate, Gemini, specifically regarding its ability to increase Interleukin-10 (IL-10) levels in a dose-dependent manner.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the reference to the attached press release. No unusual items or financial contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 to understand the specific clinical data and context of the IL-10 increases.
- Confirm the current trading status of Common Stock (REVB) and Redeemable Warrants (REVBW) on The Nasdaq Stock Market LLC.
- Review the Company's most recent 10-K or 10-Q filings for the latest financial position, as this 8-K contains no financial data.
- Assess the potential impact of the Gemini clinical results on the Company's overall development timeline and regulatory strategy.